Polyrizon Ltd is a clinical development stage biotech company specializing in the development of nasal gels to provide preventative treatment to protect against a wide cross-section of viruses, including certain variants of COVID-19 that are also considered to cause more infections and spread faster than the original strain of the virus (the CDC expects that additional variants of the virus will continue to occur), influenza, allergens, and other toxins. Its technology platforms are Capture & Contain and Trap & Target.
2005
6
LTM Revenue n/a
LTM EBITDA n/a
$16.5M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Polyrizon has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Polyrizon achieved revenue of n/a and an EBITDA of -$1.2M.
Polyrizon expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See Polyrizon valuation multiples based on analyst estimatesFY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
---|---|---|---|---|---|
Revenue | n/a | n/a | XXX | XXX | XXX |
Gross Profit | n/a | n/a | XXX | XXX | XXX |
Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
EBITDA | -$0.6M | -$1.2M | XXX | XXX | XXX |
EBITDA Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
Net Profit | -$0.8M | -$0.6M | XXX | XXX | XXX |
Net Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
Net Debt | $0.6M | $0.2M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Polyrizon's stock price is $0.
Polyrizon has current market cap of $15.9M, and EV of $16.5M.
See Polyrizon trading valuation dataEV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
---|---|---|---|---|---|---|
$16.5M | $15.9M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Polyrizon has market cap of $15.9M and EV of $16.5M.
Polyrizon's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Polyrizon's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Polyrizon and 10K+ public compsFY 2024 | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|
EV | $16.5M | XXX | XXX | XXX |
EV/Revenue | n/a | XXX | XXX | XXX |
EV/EBITDA | -13.9x | XXX | XXX | XXX |
P/E | -10.3x | XXX | XXX | XXX |
P/E/Growth | n/a | XXX | XXX | XXX |
EV/FCF | -14.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpPolyrizon's NTM/LTM revenue growth is n/a
Polyrizon's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $0.2M for the same period.
Over next 12 months, Polyrizon's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Polyrizon's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Polyrizon and other 10K+ public compsFY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|---|
Revenue Growth | n/a | XXX | XXX | XXX | XXX |
EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
EBITDA Growth | 88% | XXX | XXX | XXX | XXX |
Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
Opex per Employee | $0.2M | XXX | XXX | XXX | XXX |
S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
EV/Revenue | EV/EBITDA | |||||
---|---|---|---|---|---|---|
2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
Philips | XXX | XXX | XXX | XXX | XXX | XXX |
Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Polyrizon acquired XXX companies to date.
Last acquisition by Polyrizon was XXXXXXXX, XXXXX XXXXX XXXXXX . Polyrizon acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiplesAcquired Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign UpWhen was Polyrizon founded? | Polyrizon was founded in 2005. |
Where is Polyrizon headquartered? | Polyrizon is headquartered in United States of America. |
How many employees does Polyrizon have? | As of today, Polyrizon has 6 employees. |
Who is the CEO of Polyrizon? | Polyrizon's CEO is Mr. Tomer Izraeli. |
Is Polyrizon publicy listed? | Yes, Polyrizon is a public company listed on NAS. |
What is the stock symbol of Polyrizon? | Polyrizon trades under PLRZ ticker. |
When did Polyrizon go public? | Polyrizon went public in 2024. |
Who are competitors of Polyrizon? | Similar companies to Polyrizon include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
What is the current market cap of Polyrizon? | Polyrizon's current market cap is $15.9M |
Is Polyrizon profitable? | Yes, Polyrizon is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.